Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
For Attovia Therapeutics, Inc. (ATTO), venBio Global Strategic Fund IV, L.P. and venBio Global Strategic GP IV, LLC each may be deemed to beneficially own 4,181,366 common shares, approximately 9.2%, as of September 30, 2026. Each has shared voting and dispositive power over 4,181,366 shares. The 9.2% figure is based on 45,683,050 shares outstanding as of that date. Aaron Royston, Corey Goodman, and Richard Gaster, members of General Partner IV, disclaim beneficial ownership of the reported shares.
Beneficially owned shares4,181,366 sharesEach reporting person; as of September 30, 2026
Ownership percentageApproximately 9.2%Each reporting person; based on shares outstanding as of September 30, 2026
Shares outstanding45,683,050 sharesAs of September 30, 2026; basis for the reported ownership percentage
Key Terms
beneficial ownership, shared voting power, shared dispositive power
3 terms
beneficial ownershiptechnical
"may be deemed to beneficially own 4,181,366 shares"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
shared voting powertechnical
"shared voting power over 4,181,366 shares"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive powertechnical
"shared dispositive power over 4,181,366 shares"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many ATTO shares does venBio report beneficially owning?
venBio Global Strategic Fund IV, L.P. and venBio Global Strategic GP IV, LLC each may be deemed to beneficially own 4,181,366 ATTO common shares, approximately 9.2%, as of September 30, 2026. The percentage is based on 45,683,050 shares outstanding on that date.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Attovia Therapeutics, Inc.
(Name of Issuer)
Common stock, $0.0001 par value per share
(Title of Class of Securities)
04987L102
(CUSIP Number)
09/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
04987L102
1
Names of Reporting Persons
venBio Global Strategic Fund IV, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
4,181,366.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
4,181,366.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,181,366.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.2 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
04987L102
1
Names of Reporting Persons
venBio Global Strategic GP IV, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
4,181,366.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
4,181,366.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,181,366.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.2 %
12
Type of Reporting Person (See Instructions)
OO, HC
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Attovia Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
1091 Industrial Road, Suite 310, San Carlos, CA 94070
Item 2.
(a)
Name of person filing:
This Schedule 13G is being filed by the following persons (each a "Reporting Person" and together the "Reporting Persons"):
i. venBio Global Strategic Fund IV, L.P. ("Fund IV"); and
ii. venBio Global Strategic GP IV, LLC ("General Partner IV").
Each of Aaron Royston ("Dr. Royston"), Corey Goodman ("Dr. Goodman"), and Richard Gaster ("Dr. Gaster") is a member of General Partner IV but, in reliance on the "rule of three," disclaims beneficial ownership over the shares of Common stock, $0.0001 par value per share ("Common Stock"), reported herein as beneficially owned by the Reporting Persons.
(b)
Address or principal business office or, if none, residence:
The principal business address of each Reporting Person is 1700 Owens Street, Suite 595, San Francisco, CA 94158.
(c)
Citizenship:
i. Fund IV is a Delaware partnership; and
ii. General Partner IV is a Delaware limited liability company.
(d)
Title of class of securities:
Common stock, $0.0001 par value per share
(e)
CUSIP Number(s):
04987L102
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
As of September 30, 2026, each Reporting Person may be deemed to beneficially own 4,181,366 shares of Common Stock.
(b)
Percent of class:
As of September 30, 2026, each Reporting Person may be deemed to beneficially own approximately 9.2% of the shares of Common Stock outstanding. The beneficial ownership percentage reported herein is based on 45,683,050 shares of Common Stock outstanding as of September 30, 2026, as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2026.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
0
(ii) Shared power to vote or to direct the vote:
4,181,366
(iii) Sole power to dispose or to direct the disposition of:
0
(iv) Shared power to dispose or to direct the disposition of:
4,181,366
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
See disclosure in Item 2 hereof.
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
Not Applicable
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
venBio Global Strategic Fund IV, L.P.
Signature:
/s/ David Pezeshki
Name/Title:
David Pezeshki, as attorney-in-fact for Aaron Royston, Corey Goodman, and Richard Gaster, Members of the General Partner
Date:
11/16/2026
venBio Global Strategic GP IV, LLC
Signature:
/s/ David Pezeshki
Name/Title:
David Pezeshki, as attorney-in-fact for Aaron Royston, Corey Goodman, and Richard Gaster, Members
Date:
11/16/2026
Comments accompanying signature: This Schedule 13G was executed by David Pezeshki on behalf of the individuals listed above pursuant to a Power of Attorney, copies of which are attached as Exhibit 2 and Exhibit 3 to the Schedule 13G.
Exhibit Information
Exhibit 1: Joint Filing Agreement
Exhibit 2: Power of Attorney regarding filings under the Securities Exchange Act of 1934, as amended
Exhibit 3: Power of Attorney regarding filings under the Securities Exchange Act of 1934, as amended